Apellis Pharmaceuticals, Inc. (APLS)

May 14, 2026 - APLS was delisted (reason: acquired by BIIB)

41.03

-0.03 (-0.07%)

Inactive · Last trade price on May 13, 2026

Apellis Pharmaceuticals Financials Overview

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	1,105	1,004	781.37	396.59	75.42	66.56
Revenue Growth	42.46%	28.46%	97.02%	425.83%	13.31%	-73.44%
Gross Profit	710.47	605.69	336.07	-16.31	-317.45	-359.51
Operating Income	165.22	55.43	-164.98	-517.12	-594.61	-536.28
Net Income	133.27	22.39	-197.88	-528.63	-652.17	-746.35
Earnings Per Share	1.03	0.17	-1.60	-4.45	-6.15	-8.84
EPS Growth	-	-	-	-	-	-

Revenue by Segment

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
EMPAVELI	124.01	102.45	98.09	91.03	65.09	15.15
SYFOVRE	607.48	586.93	611.86	275.25	-	-
Licensing and Other	373.79	314.4	71.41	30.31	10.33	51.42
Revenue (Total)	1,105	1,004	781.37	396.59	75.42	66.56

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	406.2	467.79	416.14	355.54	558.31	701.23
Total Debt	475.76	474.36	469.78	110.93	112.71	210.22
Net Cash (Debt)	-69.56	-6.57	-53.65	244.61	445.59	491.01
Net Cash Growth	-	-	-	-45.10%	-9.25%	-1.78%
Net Cash Per Share	-0.53	-0.05	-0.43	2.06	4.20	5.82

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	37.77	45.33	-87.87	-594.74	-513.75	-563.13
Capital Expenditures	-0.31	-0.31	-0.4	-0.77	-1.52	-1.1
Free Cash Flow	37.47	45.01	-88.27	-595.51	-515.27	-564.23
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	64.28%	60.34%	43.01%	-4.11%	-	-
Operating Margin	14.95%	5.52%	-21.11%	-130.39%	-788.38%	-805.67%
Pretax Margin	12.23%	2.40%	-25.18%	-132.76%	-863.81%	-1120.75%
Profit Margin	12.06%	2.23%	-25.32%	-133.29%	-864.70%	-1121.28%
FCF Margin	3.39%	4.48%	-11.30%	-150.16%	-683.18%	-847.66%

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 18, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PE Ratio	39.98	141.97	-	-	-	-
P/FCF Ratio	140.20	70.61	-	-	-	-
PS Ratio	4.75	3.17	5.08	17.89	75.81	69.15